Holmes has served as Chief Operating Officer and board member for , and is a seasoned tech industry executive and AI strategist with 20+ years of business and product management experience, working with high growth venture-backed and enterprise organizations in healthcare, life sciences, energy, and financial services. Her academic background includes a Bachelor of Science and Master of Science degrees in Mechanical and Biomedical Engineering from Georgia Tech and Johns Hopkins University. She has held key roles in global consultancies including Ernst & Young, Capgemini, and Perficient. Holmes has experience in designing and implementing data and AI-driven solutions, and has held leadership roles in machine learning (ML) driven software companies across sales, product strategy, marketing, and customer success, including with Oncora Medical, focused on precision radiation oncology where she managed the company’s collaboration with MD Anderson Cancer Center.
"Over the last three years, as COO and a member of the board of directors, Angela has been instrumental in ’s growth, especially in building ’s Strategy Consulting practice and UI/UX and Machine Learning Engineering capabilities.” said Dan Watkins, former CEO of OmniScience. “It’s been a pleasure to be able to serve as the CEO of OmniScience as it was incubated and launched out of Mercury Fund, a venture capital fund based in Houston. The magic at OmniScience is all about the diverse team who have created a culture of excellence, trust and purpose with the goal of using AI/ML to solve some of the most important health and social problems facing the world today. Angela was instrumental in building our culture and customer base over the last three years and will do a great job taking the company to the next level.” Watkins will remain on the board of directors and become ’s Chief Strategy Officer.
"It is an exciting time to lead OmniScience as we advance the development of innovative data science platforms at the intersection of biology, behavior, and AI," said Holmes. "I am particularly excited about the demand for our ERGO insights platform for life sciences, allowing scientists to aggregate a vast set of biomedical data to better inform decisions around drug development priorities. The increasing understanding of biology, accessibility of large data sets, and accelerating computational capabilities is creating a golden age of life science innovation. We are committed to using our expertise to accelerate our clients’ advances in human health, nutrition, therapeutics, diagnostics, and behavior, to create profound advances for humanity."
Founded in 2017, OmniScience is a mission-driven team of data science experts partnering with our clients to build AI solutions to improve outcomes, accelerate discoveries, and enable data-driven decisions.
provides strategy consulting and software implementation services for AI solutions for life sciences and healthcare to support drug discovery, medical device connectivity, digital health applications, and clinical trials execution. The company’s data science and machine learning engineering teams have deep expertise in Computational Biology, Natural Language Processing (NLP), Neuroscience, and Pharmacology.
has been able to help its clients advance biomedical research and healthcare delivery. Example solutions include using AI to discover and prioritize new drug targets, identify digital biomarkers to increase success in clinical trials, increase clinical trial participant retention, remotely assess and monitor health via medical devices, and predict outcomes of insurance claims.
is headquartered in the Texas Medical Center in Houston. For more information, visit omniscience.bio
